Economic evaluation in collaborative hospital drug evaluation reports
Abstract Objective: economic evaluation is a fundamental criterion when deciding a drug’s place in therapy. The MADRE method (Method for Assistance in making Decisions and Writing Drug Evaluation Reports) is widely used for drug evaluation. This method was developed by the GENESIS group of the...
| Main Authors: | , , , , , |
|---|---|
| Format: | info:eu-repo/semantics/article |
| Language: | eng |
| Published: |
Aula Médica Ediciones
2016
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/10171/40160 |
| _version_ | 1793399907405529088 |
|---|---|
| author | Ortega-Eslava, A. (Ana) Fraga-Fuentes, M.D. (M.D.) Marin-Gil, R. (Roberto) Lopez-Briz, E. (Eduardo) Puigventos, F. (Francesc) Dranitsaris, G. (George) |
| author_facet | Ortega-Eslava, A. (Ana) Fraga-Fuentes, M.D. (M.D.) Marin-Gil, R. (Roberto) Lopez-Briz, E. (Eduardo) Puigventos, F. (Francesc) Dranitsaris, G. (George) |
| author_sort | Ortega-Eslava, A. (Ana) |
| collection | DSpace |
| description | Abstract
Objective: economic evaluation is a fundamental criterion
when deciding a drug’s place in therapy. The MADRE method
(Method for Assistance in making Decisions and Writing Drug
Evaluation Reports) is widely used for drug evaluation. This
method was developed by the GENESIS group of the Spanish
Society of Hospital Pharmacy (SEFH), including economic evaluation.
We intend to improve the economic aspects of this
method. As for the direction to take, we have to first analyze
our previous experiences with the current methodology and
propose necessary improvements.
Method: economic evaluation sections in collaboratively conducted
drug evaluation reports (as the scientific society, SEFH)
with the MADRE method were reviewed retrospectively.
Results: thirty-two reports were reviewed, 87.5% of them
included an economic evaluation conducted by authors and
65.6% contained published economic evaluations. In 90.6%
of the reports, a Budget impact analysis was conducted. The
cost per life year gained or per Quality Adjusted Life Year gained
was present in 14 reports. Twenty-three reports received
public comments regarding the need to improve the economic
aspect. Main difficulties: low quality evidence in the target population,
no comparative studies with a relevant comparator,
non-final outcomes evaluated, no quality of life data, no fixed
drug price available, dosing uncertainty, and different prices
for the same drug.
Conclusions: proposed improvements: incorporating different
forms of aid for non-drug costs, survival estimation and adapting
published economic evaluations; establishing criteria for
drug price selection, decision-making in conditions of uncertainty
and poor quality evidence, dose calculation and cost-effectiveness
thresholds depending on different situations |
| format | info:eu-repo/semantics/article |
| id | oai:dadun.unav.edu:10171-40160 |
| institution | Universidad de Navarra |
| language | eng |
| publishDate | 2016 |
| publisher | Aula Médica Ediciones |
| record_format | dspace |
| spelling | oai:dadun.unav.edu:10171-401602020-03-03T23:47:00Z Economic evaluation in collaborative hospital drug evaluation reports Ortega-Eslava, A. (Ana) Fraga-Fuentes, M.D. (M.D.) Marin-Gil, R. (Roberto) Lopez-Briz, E. (Eduardo) Puigventos, F. (Francesc) Dranitsaris, G. (George) Pharmacy service Hospital Pharmacy and therapeutics committee Cost effectiveness analysis Materias Investigacion::Farmacia::Farmacia y farmacología Materias Investigacion::Farmacia::Tecnología farmacéutica Budget Impact analysis Economic evaluation Servicio de farmacia de hospital Comisión de farmacia y terapéutica Análisis coste-efectividad Análisis de impacto presupuestario Evaluación económica Abstract Objective: economic evaluation is a fundamental criterion when deciding a drug’s place in therapy. The MADRE method (Method for Assistance in making Decisions and Writing Drug Evaluation Reports) is widely used for drug evaluation. This method was developed by the GENESIS group of the Spanish Society of Hospital Pharmacy (SEFH), including economic evaluation. We intend to improve the economic aspects of this method. As for the direction to take, we have to first analyze our previous experiences with the current methodology and propose necessary improvements. Method: economic evaluation sections in collaboratively conducted drug evaluation reports (as the scientific society, SEFH) with the MADRE method were reviewed retrospectively. Results: thirty-two reports were reviewed, 87.5% of them included an economic evaluation conducted by authors and 65.6% contained published economic evaluations. In 90.6% of the reports, a Budget impact analysis was conducted. The cost per life year gained or per Quality Adjusted Life Year gained was present in 14 reports. Twenty-three reports received public comments regarding the need to improve the economic aspect. Main difficulties: low quality evidence in the target population, no comparative studies with a relevant comparator, non-final outcomes evaluated, no quality of life data, no fixed drug price available, dosing uncertainty, and different prices for the same drug. Conclusions: proposed improvements: incorporating different forms of aid for non-drug costs, survival estimation and adapting published economic evaluations; establishing criteria for drug price selection, decision-making in conditions of uncertainty and poor quality evidence, dose calculation and cost-effectiveness thresholds depending on different situations Resumen Objetivo: la evaluación económica es un criterio fundamental en el posicionamiento de medicamentos. El método MADRE (Método de Ayuda para la toma de Decisiones y la Realización de Evaluaciones de medicamentos) es ampliamente utilizado en la evaluación de medicamentos. Fue desarrollado por el grupo GENESIS de la Sociedad Española de Farmacia Hospitalaria (SEFH), e incluye una evaluación económica. Con objeto de mejorar los aspectos económicos de este método, analizaremos la experiencia previa con esta metodología y propondremos mejoras. Método: revisión retrospectiva de las evaluaciones económicas en los informes de evaluación de medicamentos realizados de forma colaborativa (como SEFH) con el método MADRE. Resultados: se revisaron 32 informes, el 87,5% incluían una evaluación económica realizada por los autores y un 65,6% una publicada. El 90,6% incluían un análisis de impacto presupuestario. 14 informes incluían el coste por año de vida o por año de vida ganado ajustado por calidad. 23 informes recibieron alegaciones relacionadas con la evaluación económica. Las principales dificultades fueron: baja calidad de la evidencia en la población diana, falta de estudios comparativos con el comparador relevante, resultados finales no evaluados, falta de datos de calidad de vida, precio del medicamento no fijado, incertidumbre en la dosis y diferentes precios del medicamento. Conclusiones: mejoras propuestas: incorporar ayudas para inclusión de costes no farmacológicos, estimación de la supervivencia y adaptación de evaluaciones económicas publicadas; establecer criterios para: selección de precios, toma de decisiones en condiciones de incertidumbre o evidencia pobre, cálculo de dosis y umbrales de coste-efectividad en diferentes situaciones. 2016-03-10T11:49:01Z 2016-03-10T11:49:01Z 2015 info:eu-repo/semantics/article https://hdl.handle.net/10171/40160 eng Spanish Foundation of Hospital Pharmacy. info:eu-repo/semantics/openAccess application/pdf Aula Médica Ediciones |
| spellingShingle | Pharmacy service Hospital Pharmacy and therapeutics committee Cost effectiveness analysis Materias Investigacion::Farmacia::Farmacia y farmacología Materias Investigacion::Farmacia::Tecnología farmacéutica Budget Impact analysis Economic evaluation Servicio de farmacia de hospital Comisión de farmacia y terapéutica Análisis coste-efectividad Análisis de impacto presupuestario Evaluación económica Ortega-Eslava, A. (Ana) Fraga-Fuentes, M.D. (M.D.) Marin-Gil, R. (Roberto) Lopez-Briz, E. (Eduardo) Puigventos, F. (Francesc) Dranitsaris, G. (George) Economic evaluation in collaborative hospital drug evaluation reports |
| title | Economic evaluation in collaborative hospital drug evaluation reports |
| title_full | Economic evaluation in collaborative hospital drug evaluation reports |
| title_fullStr | Economic evaluation in collaborative hospital drug evaluation reports |
| title_full_unstemmed | Economic evaluation in collaborative hospital drug evaluation reports |
| title_short | Economic evaluation in collaborative hospital drug evaluation reports |
| title_sort | economic evaluation in collaborative hospital drug evaluation reports |
| topic | Pharmacy service Hospital Pharmacy and therapeutics committee Cost effectiveness analysis Materias Investigacion::Farmacia::Farmacia y farmacología Materias Investigacion::Farmacia::Tecnología farmacéutica Budget Impact analysis Economic evaluation Servicio de farmacia de hospital Comisión de farmacia y terapéutica Análisis coste-efectividad Análisis de impacto presupuestario Evaluación económica |
| url | https://hdl.handle.net/10171/40160 |
| work_keys_str_mv | AT ortegaeslavaaana economicevaluationincollaborativehospitaldrugevaluationreports AT fragafuentesmdmd economicevaluationincollaborativehospitaldrugevaluationreports AT maringilrroberto economicevaluationincollaborativehospitaldrugevaluationreports AT lopezbrizeeduardo economicevaluationincollaborativehospitaldrugevaluationreports AT puigventosffrancesc economicevaluationincollaborativehospitaldrugevaluationreports AT dranitsarisggeorge economicevaluationincollaborativehospitaldrugevaluationreports |